Frontiers in Pharmacology (Jan 2021)
The Role of IL-35 in the Pathophysiological Processes of Liver Disease
- Shuang Hu,
- Shuang Hu,
- Pan-pan Lian,
- Ying Hu,
- Ying Hu,
- Xing-yu Zhu,
- Shao-wei Jiang,
- Qiang Ma,
- Liang-yun Li,
- Liang-yun Li,
- Jun-fa Yang,
- Jun-fa Yang,
- Li Yang,
- Li Yang,
- Hai-yue Guo,
- Hai-yue Guo,
- Hong Zhou,
- Hong Zhou,
- Chen-chen Yang,
- Chen-chen Yang,
- Xiao-ming Meng,
- Xiao-ming Meng,
- Jun Li,
- Jun Li,
- Hai-wen Li,
- Tao Xu,
- Tao Xu,
- Huan Zhou
Affiliations
- Shuang Hu
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Shuang Hu
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Pan-pan Lian
- School of Pharmacy, NanJing University, NanJing, China
- Ying Hu
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Ying Hu
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Xing-yu Zhu
- National Drug Clinical Trial Institution, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
- Shao-wei Jiang
- The First Affiliated Hospital of Anhui Medical University, Hefei, China
- Qiang Ma
- Second Affiliated Hospital of Anhui Medical University, Hefei, China
- Liang-yun Li
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Liang-yun Li
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Jun-fa Yang
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Jun-fa Yang
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Li Yang
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Li Yang
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Hai-yue Guo
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Hai-yue Guo
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Hong Zhou
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Hong Zhou
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Chen-chen Yang
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Chen-chen Yang
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Xiao-ming Meng
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Xiao-ming Meng
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Jun Li
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Jun Li
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Hai-wen Li
- The Third Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Tao Xu
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
- Tao Xu
- Institute for Liver Diseases of Anhui Medical University, Hefei, China
- Huan Zhou
- National Drug Clinical Trial Institution, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
- DOI
- https://doi.org/10.3389/fphar.2020.569575
- Journal volume & issue
-
Vol. 11
Abstract
It is known that liver diseases have several characteristics of massive lipid accumulation and lipid metabolic disorder, and are divided into liver inflammation, liver fibrosis, liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in patients. Interleukin (IL)-35, a new-discovered cytokine, can protect the liver from the environmental attack by increasing the ratio of Tregs (T regulatory cells) which can increase the anti-inflammatory cytokines and inhibit the proliferation of immune cellular. Interestingly, two opposite mechanisms (pro-inflammatory and anti-inflammatory) have connection with the ultimate formation of liver diseases, which suggest that IL-35 may play crucial function in the process of liver diseases through immunosuppressive regulation. Besides, some obvious advantages also imply that IL-35 can be considered as a new therapeutic target to control the progression of liver diseases, while its mechanism of function still needs further research.
Keywords
